BACKGROUND: Despite being chemosensitive, the majority of @entity0 ( @entity0 ) @entity1 recur. The primary study objectives were to compare disease free survival (DFS), and overall survival (OS) for @entity0 after adjuvant chemotherapy, who underwent maintenance metronomic chemotherapy versus no maintenance therapy. METHODS: @entity0 @entity1 were eligible for enrolment if they had TNM stages II-III and fit with our inclusion criteria. @entity1 were assigned to either: group 1, 3 cycles FEC-100 then 3 cycles @entity1205 , @entity3003 , followed by maintenance metronomic chemotherapy for 1 year; and group 2, 3 cycles FEC-100 then 3 cycles @entity1205 . RESULTS: Between November 2008 and December 2014, 158 @entity1 (78 group 1, and 80 group 2) were enrolled. The mean age was 46 years. The median DFS for groups 1,2 were 28 and 24 months, respectively; P value 0.05. The median OS for groups 1,2 were 37 and 29 months, respectively; P values 0.04. Additionally, during the follow-up period, the overall distant metastasis recurrence rates for groups 1,2 were 26% and 37% respectively. Finally, treatment protocol was tolerated well in both groups with mild @entity137 profiles. CONCLUSIONS: Extended adjuvant metronomic chemotherapy achieved significant improvement in the survival and was well tolerated.

Metronomic methotrexate and cyclophosphamide after XXXX included adjuvant chemotherapy in @entity0 : a phase III study.

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity0 :: ('MESH:D001943', 'Disease') :: ['TNBC', 'triple negative breast cancer'] @entity3003 :: ('MESH:D016190', 'Chemical') :: ['carboplatin'] @entity1205 :: ('MESH:C067311', 'Chemical') :: ['docetaxel']
@entity3003 :: (MESH:D016190,Chemical) :: ['carboplatin']
